REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025. “We have made substantial progress this year across our two indications for ersodetug in both...Read more
IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close...Read more
Company to hold conference call on September 15, 2025, at 10:30 ET to review corporate highlights AUSTIN, Texas / Sep 15, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are...Read more
Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025. First Quarter and Recent Highlights: Total revenue of $14 million Adjusted EBITDA of...Read more
Strong commercial momentum driven by higher product sales Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart,...Read more
1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward CHARLOTTE, N.C., Sept. 12, 2025 (GLOBE...Read more
Cash and Cash Equivalents was $56.3 million at June 30, 2025 and the previous fiscal year. Total Revenues - Net increased 1% to $104.4 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Income from Operations decreased 30% to $11.6 million for the fiscal year ended June 30, 2025 versus the previous fiscal year. Net Income decreased 24% to $10.7 million for the fiscal year ended June 30,...Read more
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company’s website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended...Read more
EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema Initiated US EKTERLY launch in July; received 460 patient start forms through August European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October $191M in cash, providing runway into 2027 Management...Read more
Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued...Read more
KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period. Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9%...Read more
ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract...Read more
DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal fourth quarter and full year ended June 30, 2025. “Fiscal 2025 was a strong year. The combination of...Read more
Company to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Today at 8:30 a.m. ET GRAND RAPIDS, Mich., Sept. 9, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the second quarter ended...Read more
PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30,...Read more
GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Total Revenues were RMB148.5 million (US$20.7 million) for the three months...Read more
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. “This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief...Read more
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostate cancer Positive U.S. Food and Drug Administration (FDA) feedback on pathway to approval for RedHill's next-generation Crohn's disease...Read more
ALL-REMOTE COMPANY/WILMINGTON, Del. / Sep 04, 2025 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2025. “I am proud to share that Phreesia has had many noteworthy developments over the past quarter. In addition to delivering another solid set of financial results, including achieving our first-ever net income positive quarter, we have...Read more
IRVINE, CA / ACCESS Newswire / September 4, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2025 fourth quarter and full-year ended June 30, 2025. Quarter Ended June 30, 2025 Net sales for the three months ended June 30, 2025 increased $2.5 million, or 16%, to $17.5 million from $15.0 million for the three months ended June 30, 2024, due primarily to increased revenue to our top three customers....Read more
All financial results are reported in Canadian dollars unless otherwise stated. Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the...Read more
Highlights of the second quarter include: Revenue of $325.8 million, an increase of 9% compared to $299.9 million in Q2 FY25. Net income of $59.9 million, an increase of 67% compared to $35.8 million in Q2 FY25, with non-GAAP net income of $94.6 million, an increase of 24% compared to $76.3 million in Q2 FY25. Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with...Read more
Record Fourth Quarter Net Income from Continuing Operations of $15.7 Million Book Value Per Share of $2.651 as of June 30, 2025, Up 24% from Prior-Year End Over $100 Million of Recent Capital Raises in our Credit and Real Estate Products Position Company to Drive Continued Growth – Company to Host Conference Call at 8:30 a.m. ET on September 3, 2025 PALM BEACH GARDENS, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Great Elm Group,...Read more
JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30,...Read more
$1.3 Million in Operating Expense Reductions Achieved– Operating Loss Improves 19% Year-Over-Year Resilient Portfolio Performance with International Sales Despite Global Economic Uncertainties Cash Used in Operating Activities Reduced to $3.8 Million vs. $5.3 Million in the Prior Year, Reflecting Stronger Operating Discipline IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its...Read more
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and six months ended June 30, 2025. Financial and Operational Highlights Revenues were $4.7 million in the second quarter compared to $4.4 million in the same period the prior year, an increase of 6.2%. For the six months...Read more
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed interim consolidated financial statements for the three and six months ended June 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. The Company...Read more
US FDA 510(k) submission remains on track for calendar Q3 2025 Successful validation testing of Novasight Hybrid™ system with key opinion leaders Recent academic publications underscore importance of intravascular imaging and potential of hybrid IVUS / OCT $20 million financing completed in April strengthens balance sheet and supports anticipated U.S. launch TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV:...Read more
Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with...Read more
Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development Launch of Celea Therapeutics continues our proven, capital-efficient model Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents and short-term investments and $319.9M Consolidated cash, cash equivalents and short-term investments as...Read more
+140% Focal One® Net Placement Growth Year over Year +76.8% HIFU Revenue Growth Year over Year 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion Company raises 2025 HIFU Year over Year Revenue Growth Guidance range to 26% to 34%, up from the prior range of 16% to 25% Company to Host Conference Call and Webcast Today, August 28th, at...Read more
TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the second quarter ended June 30, 2025 (“Q2”), and provide a corporate update on its recent activities and upcoming...Read more
CALGARY, AB, Aug. 28, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications announces second quarter results for the period ending on June 30, 2025. Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 5...Read more
Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite’s...Read more
All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended June 30, 2025 (“Q2 2025”), and provided an update on recent...Read more
TEL AVIV, Israel, Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three and six months ended June 30, 2025 and recent developments. Recent Business Updates In August 2025, Galmed announced that it has adopted a digital asset management strategy...Read more
WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results. Second Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended June 30, 2025 was $27,997 compared to $620,437 in the three months ended June 30, 2024. Almost...Read more
Total Revenues of $789.1M, up 17% Year Over Year Subscription Services Revenues of $659.2M, up 17% Year Over Year PLEASANTON, Calif., Aug. 27, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2025. "It's exciting to see our vision of connected software, data, and business...Read more
Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core(1) basis compared with the third quarter of 2024. GAAP net income of $336 million; earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024. Non-GAAP(2) net income of $390 million; EPS...Read more
SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million. GAAP diluted earnings per share (EPS) of $0.49,...Read more
TEANECK, N.J. / Aug 27, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5...Read more
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gains Ongoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory discussions, including seeking alignment with FDA on potential expedited approval...Read more
Record quarterly and annual revenues and operating income, marking the eleventh consecutive quarter of year-over-year revenue and operating income growth NEW PRAGUE, Minn. / Aug 26, 2025 / Business Wire / Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2025") and full year ended June 30, 2025 ("FY 2025"). Q4 FY...Read more
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 2Q2025 financial statements ("Financial Statements"). Theralase® will...Read more
Conference Call/Webcast Today at 5 pm ET TORONTO and DALLAS, Aug. 26, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported financial results for its second quarter ended June 30, 2025 and provided a corporate update. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars...Read more
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025 IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano Med Appointed...Read more
TORONTO / Aug 25, 2025 / Business Wire / Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health”, “JNH” or the “Company”) announced today its unaudited interim consolidated financial results for the first quarter of fiscal 2026, three months ended April 30, 2025. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). Management Commentary Mike...Read more
Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first potential eye drop to treat diabetic macular edema (DME) Privosegtor (OCS-05): Preparing to initiate Phase 2/3 trial in acute optic neuritis (AON) in 1H 2026 following positive Ph2 ACUITY results, and expanding clinical...Read more
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights include: (CAD) Q2 2025 % Change vs.Q2 2024 H1 2025 % Change vs. H1 2024 Trailing Twelve Months (TTM)June 30, 2025 % Changevs. TTM June 30, 2024 Canadian...Read more
Sequential QoQ Revenue Growth of 10.4%, Adjusted EBITDA Growth of 52% Trailing Twelve Months Revenue Growth of 13%, Adjusted EBITDA Growth of 116% MISSISSAUGA, Ontario / Aug 21, 2025 / Business Wire / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 third quarter results for the period ended June 30, 2025, along with a number of...Read more
MONTRÉAL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Company”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its third quarter ended on June 30, 2025. Highlights (in thousands of Canadian dollars) June 30, 2025(3 months ) June 30, 2024(3 months ) June 30, 2025(9 months ) June 30, 2024(9...Read more
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China’s NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK...Read more
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results1 Group performance2: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%3 and on track to meet full year...Read more
Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion study Topline data from planned dose expansion study of givastomig expected in Q1 2026 Strengthened balance sheet with net proceeds of approximately $61.2 million from August 2025 underwritten offering; pro-forma cash balance of...Read more
Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire Raised $3.6 million in registered direct offering in second quarter REHOVOT, Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue...Read more
All financial results are reported in Canadian dollars unless otherwise stated. Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for...Read more
WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2025. Quarter Ended June 30, 2025 Highlights: Recorded total net revenue of $6.7...Read more
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029...Read more
TAMPA, FLORIDA / ACCESS Newswire / August 20, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced financial results for the second fiscal quarter ended June 30, 2025. Financial Results Revenue on a pro forma basis, which reflects results as if Wellgistics' distribution...Read more
11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8%...Read more
Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the...Read more
Fourth-quarter total net revenue of $262.9 million was better than the company expected (total net revenue excluding Contigo Health* of $258.0 million) Fourth-quarter GAAP net income from continuing operations of $18.0 million, or $0.22 per fully diluted share Fourth-quarter adjusted EPS of $0.46, excluding Contigo Health* contributed to full-year adjusted EPS that was above the high end of the company’s guidance range Full-year net...Read more
Adjusted EBITDA increases 5% FXN YoY with all segments contributing positively to quarterly results in their local currency LUXEMBOURG / Aug 19, 2025 / Business Wire / Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, today announced financial results for the second quarter ended June 30, 2025 (“second quarter 2025” or “2Q25”). Financial results...Read more
U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following End of Phase 2 Meeting FDA End of Phase 2 Meeting scheduled for August 27, 2025 to review Phase 2b clinical trial in the prevention or delay of recurrent, pulmonary metastatic osteosarcoma Statistically significant 12-month Event...Read more
POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025. Highlights in the quarter include: Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's disease Progress in the...Read more
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company...Read more
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation...Read more
FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of...Read more
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a...Read more
CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025 Income StatementCosmos Health continued its positive trajectory in Q2 2025, delivering...Read more
MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025. On May 15,...Read more
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pending patent litigation in the U.S....Read more
BEIJING, Aug. 15, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Total revenues were RMB378.7 million (US$52.9 million[1]), compared with...Read more
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoing Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025 Following recent transactions,...Read more
Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company...Read more
Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company...Read more
BOULDER, CO / ACCESS Newswire / August 15, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 first quarter that ended June 30, 2025. The Company posted quarterly product net revenue of $1.49 million and service net revenue of $110...Read more
Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / August 15, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the...Read more
Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial Hazard ratios and improvements in median progression-free survival (“PFS”) are unprecedented in HR+/HER2- advanced breast cancer (“ABC”) Expect to submit a New Drug Application (“NDA”) for gedatolisib, based on data from the PIK3CA wild-type cohort, to the U.S. Food and...Read more
WELL achieved record quarterly revenues of $356.7 million in Q2-2025, an increase of 57% compared to Q2-2024 driven by organic growth and acquisitions. Excluding the impact from Circle Medical’s deferred revenue adjustments or “CM Deferrals”, revenue would have been $347.0 million in Q2-2025, representing 53% year-over-year growth. Results were positively impacted during the quarter by the addition of $40.5 million of revenue from the...Read more
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and...Read more
Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 CARLSBAD, Calif., Aug. 14, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities...Read more
Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential Biologics License Application (BLA) filing; on track for potential data readout late 2026 FDA Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson’s disease In...Read more
Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-date Made principal repayments on the Company's long-term debt totalling $8.5 million Expanded cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion Therapeutics TORONTO, Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company...Read more
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label study FDA recommended...Read more
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “We are encouraged by the continued analysis of data from our NAVIGATE trial ,...Read more
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase...Read more
Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage...Read more
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data...Read more
Conference Call Today at 4:30 p.m. ET SEATTLE / Aug 14, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE